5 Reasons why Axsome Therapeutics Could Take off now!
Mizuho raises target from 137 to 195 USD (Outperform)
Sales multiplication by 2027 and P/E ratio estimate under 12
Reading Time: 1 minute
Axsome Therapeutics (AXSM) specializes in treatments for the central nervous system (CNS) and could potentially reach 150 million people in the USA with its products. Here are five concrete reasons why the stock is likely to rise further: Axsome Therapeutics has resolved its patent dispute with Teva regarding its core product Auvelity (AXS-05). A generic version of the antidepressant is not expected until at least 2038. Mizuho therefore sees a 50% chance. The FDA approval for Symbravo (AXS-07) for acute migraine treatment could address a...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
